These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 2467654

  • 1. Recombinant human granulocyte colony stimulating factors: therapeutic application in the prevention of chemotherapy-induced neutropenia.
    Gabrilove JL, Jakubowski A, Scher H, Sternberg C, Wong G, Grous J, Yagoda A, Fain K, Moore MA, Clarkson B.
    Behring Inst Mitt; 1988 Aug; (83):229-33. PubMed ID: 2467654
    [No Abstract] [Full Text] [Related]

  • 2. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium.
    Gabrilove JL, Jakubowski A, Scher H, Sternberg C, Wong G, Grous J, Yagoda A, Fain K, Moore MA, Clarkson B, Oettgen HF, Alton K, Welte K, Souza L.
    N Engl J Med; 1988 Jun 02; 318(22):1414-22. PubMed ID: 2452983
    [Abstract] [Full Text] [Related]

  • 3. Effect of recombinant human granulocyte colony-stimulating factor in patients receiving methotrexate/vinblastine/doxorubicin/cisplatin therapy for the treatment of transitional cell carcinoma of the urinary tract.
    Akaza H, Kotake T, Miyanaga N, Koiso K.
    Semin Oncol; 1994 Feb 02; 21(1 Suppl 1):70-4. PubMed ID: 7512280
    [No Abstract] [Full Text] [Related]

  • 4. Impact of recombinant human granulocyte colony stimulating factor on dose intensity and toxicity of three cycles of methotrexate, vinblastine, doxorubicin and cisplatin in patients with previously untreated urothelial bladder carcinoma.
    Viens P, Gravis G, Bladou F, Lechevallier E, Baume D, Camerlo J, Cowen D, Coulange C, Serment G, Resbeut M, Maraninchi D.
    Eur Cytokine Netw; 1996 Sep 02; 7(3):395-9. PubMed ID: 8954183
    [Abstract] [Full Text] [Related]

  • 5. [M-VAC chemotherapy for advanced urothelial cancer--side effects and their management].
    Noguchi S, Kubota Y, Shuin T, Masuda M, Misaki H, Yao M, Kondoh K, Sakuramoto T, Hosaka M.
    Hinyokika Kiyo; 1994 Aug 02; 40(8):677-82. PubMed ID: 7942364
    [Abstract] [Full Text] [Related]

  • 6. Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer.
    Bronchud M, Scarffe JH, Thatcher N, Crowther D, Souza LM, Alton NK, Testa NG, Dexter TM.
    Behring Inst Mitt; 1988 Aug 02; (83):327-9. PubMed ID: 2467655
    [Abstract] [Full Text] [Related]

  • 7. Shorter interval between cycles of cyclophosphamide, doxorubicin, cisplatin using recombinant human granulocyte colony-stimulating factor for urothelial cancer--phase I/II study.
    Yoshida O, Kakehi Y, Arai Y, Tomoyoshi T, Okada Y, Matsuda T, Mikami O, Fukuyama T, Hida S, Okabe T.
    Int J Urol; 1995 Nov 02; 2(5):316-21. PubMed ID: 8749950
    [Abstract] [Full Text] [Related]

  • 8. In-vitro cell growth of human urothelial tumor cell lines under exposure with IL-3, GM-CSF, G-CSF and by combined administration with methotrexate, vinblastine, adriamycin and cisplatin.
    Block T, Treiber U, Geffken B, Vogel M, Hanauske AR, Busch R, Hartung R.
    Investig Urol (Berl); 1994 Nov 02; 5():91-4. PubMed ID: 7536524
    [No Abstract] [Full Text] [Related]

  • 9. [Effect of recombinant human granulocyte colony stimulating factor (rhG-CSF) in patients receiving chemotherapy--phase I study].
    Fukutani H, Ogawa M, Horikoshi N, Inoue K, Mukaiyama T, Nagamine D, Shinagawa K, Tabata M, Hirano A, Mizunuma N.
    Gan To Kagaku Ryoho; 1989 May 02; 16(5):2005-12. PubMed ID: 2471461
    [Abstract] [Full Text] [Related]

  • 10. The effects of recombinant human granulocyte-macrophage colony-stimulating factor on phagocyte kinetics in man.
    Linch DC, Devereux S, Addison IE.
    Behring Inst Mitt; 1988 Aug 02; (83):320-3. PubMed ID: 3071347
    [Abstract] [Full Text] [Related]

  • 11. Clinical studies with granulocyte colony stimulating factor (G-CSF) in patients receiving cytotoxic chemotherapy.
    Morstyn G, Campbell L, Dührsen U, Souza LM, Alton NK, Villeval JL, Nicola NA, Boyd AW, Kannourakis G, Cebon J.
    Behring Inst Mitt; 1988 Aug 02; (83):234-9. PubMed ID: 2467651
    [Abstract] [Full Text] [Related]

  • 12. Chemotherapy for advanced urothelial cancer.
    Yagoda A.
    Semin Urol; 1983 Feb 02; 1(1):60-74. PubMed ID: 6382528
    [No Abstract] [Full Text] [Related]

  • 13. Escalated therapy for refractory urothelial tumors: methotrexate-vinblastine-doxorubicin-cisplatin plus unglycosylated recombinant human granulocyte-macrophage colony-stimulating factor.
    Logothetis CJ, Dexeus FH, Sella A, Amato RJ, Kilbourn RG, Finn L, Gutterman JU.
    J Natl Cancer Inst; 1990 Apr 18; 82(8):667-72. PubMed ID: 2181151
    [Abstract] [Full Text] [Related]

  • 14. Granulocyte colony-stimulating factor (G-CSF) prevents dose-limiting neutropenia in lymphoma patients receiving standard dose chemotherapy.
    Dotti G, Stella CC, Mangoni L, Cottafavi L, Caramatti C, Almici C, Rizzoli V.
    Haematologica; 1995 Apr 18; 80(2):142-5. PubMed ID: 7543069
    [Abstract] [Full Text] [Related]

  • 15. Acute arterial thrombosis after escalated-dose methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy with recombinant granulocyte colony-stimulating factor. A possible new recombinant granulocyte colony-stimulating factor toxicity.
    Conti JA, Scher HI.
    Cancer; 1992 Dec 01; 70(11):2699-702. PubMed ID: 1384952
    [Abstract] [Full Text] [Related]

  • 16. Granulocyte colony-stimulating factors in the management of chemotherapy-induced neutropenia: evidence based review.
    Bhana N.
    Curr Opin Oncol; 2007 Jul 01; 19(4):328-35. PubMed ID: 17545795
    [Abstract] [Full Text] [Related]

  • 17. Human recombinant hemopoietic growth factors G-CSF and GM-CSF: first results of clinical trials.
    Nissen-Druey C.
    Nouv Rev Fr Hematol (1978); 1989 Jul 01; 31(2):99-101. PubMed ID: 2475852
    [No Abstract] [Full Text] [Related]

  • 18. Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.
    Edelman MJ, Meyers FJ, Houston J, Lauder I.
    Semin Oncol; 1997 Oct 01; 24(5 Suppl 15):S15-68-S15-71. PubMed ID: 9346226
    [Abstract] [Full Text] [Related]

  • 19. Effect of granulocyte-macrophage colony-stimulating factor on neutropenia and related morbidity induced by myelotoxic chemotherapy.
    Herrmann F, Schulz G, Wieser M, Kolbe K, Nicolay U, Noack M, Lindemann A, Mertelsmann R.
    Am J Med; 1990 Jun 01; 88(6):619-24. PubMed ID: 2189305
    [Abstract] [Full Text] [Related]

  • 20. Phase I study of recombinant DNA granulocyte macrophage colony stimulating factor.
    Steward WP, Scarffe JH, Austin R, Crowther D.
    Behring Inst Mitt; 1988 Aug 01; (83):324-6. PubMed ID: 3071348
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.